Yuliya Lytvyn, Lucas C Godoy, Rosalie A Scholtes, Daniël H van Raalte, David Z Cherney. Curr Diab Rep 2019
Times Cited: 5
Times Cited: 5
Times Cited
Times Co-cited
Similarity
Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial.
Ofri Mosenzon, Stephen D Wiviott, Avivit Cahn, Aliza Rozenberg, Ilan Yanuv, Erica L Goodrich, Sabina A Murphy, Hiddo J L Heerspink, Thomas A Zelniker, Jamie P Dwyer,[...]. Lancet Diabetes Endocrinol 2019
Ofri Mosenzon, Stephen D Wiviott, Avivit Cahn, Aliza Rozenberg, Ilan Yanuv, Erica L Goodrich, Sabina A Murphy, Hiddo J L Heerspink, Thomas A Zelniker, Jamie P Dwyer,[...]. Lancet Diabetes Endocrinol 2019
60
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
Christoph Wanner, Silvio E Inzucchi, John M Lachin, David Fitchett, Maximilian von Eynatten, Michaela Mattheus, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Bernard Zinman. N Engl J Med 2016
Christoph Wanner, Silvio E Inzucchi, John M Lachin, David Fitchett, Maximilian von Eynatten, Michaela Mattheus, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Bernard Zinman. N Engl J Med 2016
60
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Vlado Perkovic, Meg J Jardine, Bruce Neal, Severine Bompoint, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris, Scott Bull,[...]. N Engl J Med 2019
Vlado Perkovic, Meg J Jardine, Bruce Neal, Severine Bompoint, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris, Scott Bull,[...]. N Engl J Med 2019
60
Diabetic nephropathy: an insight into molecular mechanisms and emerging therapies.
Annabelle M Warren, Søren T Knudsen, Mark E Cooper. Expert Opin Ther Targets 2019
Annabelle M Warren, Søren T Knudsen, Mark E Cooper. Expert Opin Ther Targets 2019
40
Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes.
David Z I Cherney, Bruce A Perkins, Nima Soleymanlou, Fengxia Xiao, Joseph Zimpelmann, Hans-Juergen Woerle, Odd E Johansen, Uli C Broedl, Maximilian von Eynatten, Kevin D Burns. Kidney Int 2014
David Z I Cherney, Bruce A Perkins, Nima Soleymanlou, Fengxia Xiao, Joseph Zimpelmann, Hans-Juergen Woerle, Odd E Johansen, Uli C Broedl, Maximilian von Eynatten, Kevin D Burns. Kidney Int 2014
40
Acute Effect of Empagliflozin on Fractional Excretion of Sodium and eGFR in Youth With Type 2 Diabetes.
Petter Bjornstad, Lori Laffel, William V Tamborlane, Gudrun Simons, Stefan Hantel, Maximilian von Eynatten, Jyothis George, Jan Marquard, David Z I Cherney. Diabetes Care 2018
Petter Bjornstad, Lori Laffel, William V Tamborlane, Gudrun Simons, Stefan Hantel, Maximilian von Eynatten, Jyothis George, Jan Marquard, David Z I Cherney. Diabetes Care 2018
40
SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis.
Brendon L Neuen, Tamara Young, Hiddo J L Heerspink, Bruce Neal, Vlado Perkovic, Laurent Billot, Kenneth W Mahaffey, David M Charytan, David C Wheeler, Clare Arnott,[...]. Lancet Diabetes Endocrinol 2019
Brendon L Neuen, Tamara Young, Hiddo J L Heerspink, Bruce Neal, Vlado Perkovic, Laurent Billot, Kenneth W Mahaffey, David M Charytan, David C Wheeler, Clare Arnott,[...]. Lancet Diabetes Endocrinol 2019
40
Evaluation of Glomerular Hemodynamic Function by Empagliflozin in Diabetic Mice Using In Vivo Imaging.
Kengo Kidokoro, David Z I Cherney, Andrea Bozovic, Hajime Nagasu, Minoru Satoh, Eiichiro Kanda, Tamaki Sasaki, Naoki Kashihara. Circulation 2019
Kengo Kidokoro, David Z I Cherney, Andrea Bozovic, Hajime Nagasu, Minoru Satoh, Eiichiro Kanda, Tamaki Sasaki, Naoki Kashihara. Circulation 2019
40
Sodium glucose cotransporter 2 inhibition and renal ischemia: implications for future clinical trials.
Daniël H van Raalte, David Z I Cherney. Kidney Int 2018
Daniël H van Raalte, David Z I Cherney. Kidney Int 2018
40
No Need to Sugarcoat the Message: Is Cardiovascular Risk Reduction From SGLT2 Inhibition Related to Natriuresis?
Bruce A Perkins, Jacob A Udell, David Z I Cherney. Am J Kidney Dis 2016
Bruce A Perkins, Jacob A Udell, David Z I Cherney. Am J Kidney Dis 2016
40
Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.
George L Bakris, Rajiv Agarwal, Juliana C Chan, Mark E Cooper, Ron T Gansevoort, Hermann Haller, Giuseppe Remuzzi, Peter Rossing, Roland E Schmieder, Christina Nowack,[...]. JAMA 2015
George L Bakris, Rajiv Agarwal, Juliana C Chan, Mark E Cooper, Ron T Gansevoort, Hermann Haller, Giuseppe Remuzzi, Peter Rossing, Roland E Schmieder, Christina Nowack,[...]. JAMA 2015
40
The Metabolodiuretic Promise of Sodium-Dependent Glucose Cotransporter 2 Inhibition: The Search for the Sweet Spot in Heart Failure.
Subodh Verma, John J V McMurray, David Z I Cherney. JAMA Cardiol 2017
Subodh Verma, John J V McMurray, David Z I Cherney. JAMA Cardiol 2017
40
Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin.
David Z I Cherney, Mark E Cooper, Ilkka Tikkanen, Egon Pfarr, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Søren S Lund. Kidney Int 2018
David Z I Cherney, Mark E Cooper, Ilkka Tikkanen, Egon Pfarr, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Søren S Lund. Kidney Int 2018
40
Sodium-glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy.
Marko Škrtić, David Z I Cherney. Curr Opin Nephrol Hypertens 2015
Marko Škrtić, David Z I Cherney. Curr Opin Nephrol Hypertens 2015
40
Renoprotective effects of sodium-glucose cotransporter-2 inhibitors.
Hiddo J L Heerspink, Mikhail Kosiborod, Silvio E Inzucchi, David Z I Cherney. Kidney Int 2018
Hiddo J L Heerspink, Mikhail Kosiborod, Silvio E Inzucchi, David Z I Cherney. Kidney Int 2018
40
Diabetic Kidney Disease in Adolescents With Type 2 Diabetes: New Insights and Potential Therapies.
Petter Bjornstad, David Z Cherney, David M Maahs, Kristen J Nadeau. Curr Diab Rep 2016
Petter Bjornstad, David Z Cherney, David M Maahs, Kristen J Nadeau. Curr Diab Rep 2016
40
Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers.
Claire C J Dekkers, Sergei Petrykiv, Gozewijn D Laverman, David Z Cherney, Ron T Gansevoort, Hiddo J L Heerspink. Diabetes Obes Metab 2018
Claire C J Dekkers, Sergei Petrykiv, Gozewijn D Laverman, David Z Cherney, Ron T Gansevoort, Hiddo J L Heerspink. Diabetes Obes Metab 2018
40
Use of Canagliflozin in Kidney Transplant Recipients for the Treatment of Type 2 Diabetes: A Case Series.
Harindra Rajasekeran, S Joseph Kim, Carl J Cardella, Jeffrey Schiff, Mark Cattral, David Z I Cherney, Sunita K S Singh. Diabetes Care 2017
Harindra Rajasekeran, S Joseph Kim, Carl J Cardella, Jeffrey Schiff, Mark Cattral, David Z I Cherney, Sunita K S Singh. Diabetes Care 2017
40
Sodium-glucose cotransporter 2 inhibition and cardiovascular risk reduction in patients with type 2 diabetes: the emerging role of natriuresis.
Harindra Rajasekeran, Yuliya Lytvyn, David Z I Cherney. Kidney Int 2016
Harindra Rajasekeran, Yuliya Lytvyn, David Z I Cherney. Kidney Int 2016
40
Canagliflozin Prevents Intrarenal Angiotensinogen Augmentation and Mitigates Kidney Injury and Hypertension in Mouse Model of Type 2 Diabetes Mellitus.
T Cooper Woods, Ryousuke Satou, Kayoko Miyata, Akemi Katsurada, Courtney M Dugas, Natasha C Klingenberg, Vivian A Fonseca, L Gabriel Navar. Am J Nephrol 2019
T Cooper Woods, Ryousuke Satou, Kayoko Miyata, Akemi Katsurada, Courtney M Dugas, Natasha C Klingenberg, Vivian A Fonseca, L Gabriel Navar. Am J Nephrol 2019
40
Antihyperglycemic agents as novel natriuretic therapies in diabetic kidney disease.
David León Jiménez, David Z I Cherney, Petter Bjornstad, Luis Castilla-Guerra, José Pablo Miramontes González. Am J Physiol Renal Physiol 2018
David León Jiménez, David Z I Cherney, Petter Bjornstad, Luis Castilla-Guerra, José Pablo Miramontes González. Am J Physiol Renal Physiol 2018
40
Perioperative Considerations for the Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes.
Sharon C Peacock, Julie A Lovshin, David Z I Cherney. Anesth Analg 2018
Sharon C Peacock, Julie A Lovshin, David Z I Cherney. Anesth Analg 2018
40
Sodium-glucose cotransporter 2 inhibition in type 1 diabetes: simultaneous glucose lowering and renal protection?
David Z I Cherney, Bruce A Perkins. Can J Diabetes 2014
David Z I Cherney, Bruce A Perkins. Can J Diabetes 2014
40
Do effects of sodium-glucose cotransporter-2 inhibitors in patients with diabetes give insight into potential use in non-diabetic kidney disease?
Harindra Rajasekeran, David Z Cherney, Julie A Lovshin. Curr Opin Nephrol Hypertens 2017
Harindra Rajasekeran, David Z Cherney, Julie A Lovshin. Curr Opin Nephrol Hypertens 2017
40
The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes.
David Cherney, Søren S Lund, Bruce A Perkins, Per-Henrik Groop, Mark E Cooper, Stefan Kaspers, Egon Pfarr, Hans J Woerle, Maximilian von Eynatten. Diabetologia 2016
David Cherney, Søren S Lund, Bruce A Perkins, Per-Henrik Groop, Mark E Cooper, Stefan Kaspers, Egon Pfarr, Hans J Woerle, Maximilian von Eynatten. Diabetologia 2016
40
The effect of sodium/glucose cotransporter 2 (SGLT2) inhibition on the urinary proteome.
David Cherney, Bruce A Perkins, Yuliya Lytvyn, Hiddo Heerspink, María E Rodríguez-Ortiz, Harald Mischak. PLoS One 2017
David Cherney, Bruce A Perkins, Yuliya Lytvyn, Hiddo Heerspink, María E Rodríguez-Ortiz, Harald Mischak. PLoS One 2017
40
Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration.
Marko Skrtić, Gary K Yang, Bruce A Perkins, Nima Soleymanlou, Yuliya Lytvyn, Maximilian von Eynatten, Hans J Woerle, Odd Erik Johansen, Uli C Broedl, Thomas Hach,[...]. Diabetologia 2014
Marko Skrtić, Gary K Yang, Bruce A Perkins, Nima Soleymanlou, Yuliya Lytvyn, Maximilian von Eynatten, Hans J Woerle, Odd Erik Johansen, Uli C Broedl, Thomas Hach,[...]. Diabetologia 2014
40
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
40
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
40
The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus.
David Zi Cherney, Bruce A Perkins, Nima Soleymanlou, Ronnie Har, Nora Fagan, Odd Erik Johansen, Hans-Juergen Woerle, Maximilian von Eynatten, Uli C Broedl. Cardiovasc Diabetol 2014
David Zi Cherney, Bruce A Perkins, Nima Soleymanlou, Ronnie Har, Nora Fagan, Odd Erik Johansen, Hans-Juergen Woerle, Maximilian von Eynatten, Uli C Broedl. Cardiovasc Diabetol 2014
40
Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus.
David Z I Cherney, Bruce A Perkins, Nima Soleymanlou, Maria Maione, Vesta Lai, Alana Lee, Nora M Fagan, Hans J Woerle, Odd Erik Johansen, Uli C Broedl,[...]. Circulation 2014
David Z I Cherney, Bruce A Perkins, Nima Soleymanlou, Maria Maione, Vesta Lai, Alana Lee, Nora M Fagan, Hans J Woerle, Odd Erik Johansen, Uli C Broedl,[...]. Circulation 2014
40
Dapagliflozin in focal segmental glomerulosclerosis: a combined human-rodent pilot study.
Harindra Rajasekeran, Heather N Reich, Michelle A Hladunewich, Daniel Cattran, Julie A Lovshin, Yuliya Lytvyn, Petter Bjornstad, Vesta Lai, Josephine Tse, Leslie Cham,[...]. Am J Physiol Renal Physiol 2018
Harindra Rajasekeran, Heather N Reich, Michelle A Hladunewich, Daniel Cattran, Julie A Lovshin, Yuliya Lytvyn, Petter Bjornstad, Vesta Lai, Josephine Tse, Leslie Cham,[...]. Am J Physiol Renal Physiol 2018
40
Urinary adenosine excretion in type 1 diabetes.
Harindra Rajasekeran, Yuliya Lytvyn, Andrea Bozovic, Julie A Lovshin, Eleftherios Diamandis, Daniel Cattran, Mansoor Husain, Bruce A Perkins, Andrew Advani, Heather N Reich,[...]. Am J Physiol Renal Physiol 2017
Harindra Rajasekeran, Yuliya Lytvyn, Andrea Bozovic, Julie A Lovshin, Eleftherios Diamandis, Daniel Cattran, Mansoor Husain, Bruce A Perkins, Andrew Advani, Heather N Reich,[...]. Am J Physiol Renal Physiol 2017
40
Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
Hiddo J L Heerspink, Bruce A Perkins, David H Fitchett, Mansoor Husain, David Z I Cherney. Circulation 2016
Hiddo J L Heerspink, Bruce A Perkins, David H Fitchett, Mansoor Husain, David Z I Cherney. Circulation 2016
40
Sodium transport in diabetes: two sides to the coin.
Julie A Lovshin, David Z Cherney. Nat Rev Nephrol 2019
Julie A Lovshin, David Z Cherney. Nat Rev Nephrol 2019
40
How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial.
Silvio E Inzucchi, Bernard Zinman, David Fitchett, Christoph Wanner, Ele Ferrannini, Martin Schumacher, Claudia Schmoor, Kristin Ohneberg, Odd Erik Johansen, Jyothis T George,[...]. Diabetes Care 2018
Silvio E Inzucchi, Bernard Zinman, David Fitchett, Christoph Wanner, Ele Ferrannini, Martin Schumacher, Claudia Schmoor, Kristin Ohneberg, Odd Erik Johansen, Jyothis T George,[...]. Diabetes Care 2018
40
Use of Sodium Glucose Cotransporter 2 Inhibitors in the Hands of Cardiologists: With Great Power Comes Great Responsibility.
David Z I Cherney, Jacob A Udell. Circulation 2016
David Z I Cherney, Jacob A Udell. Circulation 2016
40
Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.
David Z I Cherney, Bernard Zinman, Silvio E Inzucchi, Audrey Koitka-Weber, Michaela Mattheus, Maximilian von Eynatten, Christoph Wanner. Lancet Diabetes Endocrinol 2017
David Z I Cherney, Bernard Zinman, Silvio E Inzucchi, Audrey Koitka-Weber, Michaela Mattheus, Maximilian von Eynatten, Christoph Wanner. Lancet Diabetes Endocrinol 2017
40
Liraglutide and Renal Outcomes in Type 2 Diabetes.
Johannes F E Mann, David D Ørsted, Kirstine Brown-Frandsen, Steven P Marso, Neil R Poulter, Søren Rasmussen, Karen Tornøe, Bernard Zinman, John B Buse. N Engl J Med 2017
Johannes F E Mann, David D Ørsted, Kirstine Brown-Frandsen, Steven P Marso, Neil R Poulter, Søren Rasmussen, Karen Tornøe, Bernard Zinman, John B Buse. N Engl J Med 2017
40
US Renal Data System 2010 Annual Data Report.
Allan J Collins, Robert N Foley, Charles Herzog, Blanche Chavers, David Gilbertson, Areef Ishani, Bertram Kasiske, Jiannong Liu, Lih-Wen Mau, Marshall McBean,[...]. Am J Kidney Dis 2011
Allan J Collins, Robert N Foley, Charles Herzog, Blanche Chavers, David Gilbertson, Areef Ishani, Bertram Kasiske, Jiannong Liu, Lih-Wen Mau, Marshall McBean,[...]. Am J Kidney Dis 2011
40
The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure.
Merlin C Thomas, David Z I Cherney. Diabetologia 2018
Merlin C Thomas, David Z I Cherney. Diabetologia 2018
40
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
40
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.
Hiddo J L Heerspink, Hans-Henrik Parving, Dennis L Andress, George Bakris, Ricardo Correa-Rotter, Fan-Fan Hou, Dalane W Kitzman, Donald Kohan, Hirofumi Makino, John J V McMurray,[...]. Lancet 2019
Hiddo J L Heerspink, Hans-Henrik Parving, Dennis L Andress, George Bakris, Ricardo Correa-Rotter, Fan-Fan Hou, Dalane W Kitzman, Donald Kohan, Hirofumi Makino, John J V McMurray,[...]. Lancet 2019
40
Update of pathophysiology and management of diabetic kidney disease.
Yi-Chih Lin, Yu-Hsing Chang, Shao-Yu Yang, Kwan-Dun Wu, Tzong-Shinn Chu. J Formos Med Assoc 2018
Yi-Chih Lin, Yu-Hsing Chang, Shao-Yu Yang, Kwan-Dun Wu, Tzong-Shinn Chu. J Formos Med Assoc 2018
40
Inhibition of Src kinase blocks high glucose-induced EGFR transactivation and collagen synthesis in mesangial cells and prevents diabetic nephropathy in mice.
Kanta Taniguchi, Ling Xia, Howard J Goldberg, Ken W K Lee, Anu Shah, Laura Stavar, Elodie A Y Masson, Abdul Momen, Eric A Shikatani, Rohan John,[...]. Diabetes 2013
Kanta Taniguchi, Ling Xia, Howard J Goldberg, Ken W K Lee, Anu Shah, Laura Stavar, Elodie A Y Masson, Abdul Momen, Eric A Shikatani, Rohan John,[...]. Diabetes 2013
20
Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial.
Anthony H Barnett, Ambrish Mithal, Jenny Manassie, Russell Jones, Henning Rattunde, Hans J Woerle, Uli C Broedl. Lancet Diabetes Endocrinol 2014
Anthony H Barnett, Ambrish Mithal, Jenny Manassie, Russell Jones, Henning Rattunde, Hans J Woerle, Uli C Broedl. Lancet Diabetes Endocrinol 2014
20
Elevated glucose impairs endothelium-dependent relaxation by activating protein kinase C.
B Tesfamariam, M L Brown, R A Cohen. J Clin Invest 1991
B Tesfamariam, M L Brown, R A Cohen. J Clin Invest 1991
20
The efficacy and safety of lixivaptan in outpatients with heart failure and volume overload: results of a multicentre, randomized, double-blind, placebo-controlled, parallel-group study.
Jalal K Ghali, Cesare Orlandi, William T Abraham. Eur J Heart Fail 2012
Jalal K Ghali, Cesare Orlandi, William T Abraham. Eur J Heart Fail 2012
20
Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes.
William T Cefalu, Kaj Stenlöf, Lawrence A Leiter, John P H Wilding, Lawrence Blonde, David Polidori, John Xie, Daniel Sullivan, Keith Usiskin, William Canovatchel,[...]. Diabetologia 2015
William T Cefalu, Kaj Stenlöf, Lawrence A Leiter, John P H Wilding, Lawrence Blonde, David Polidori, John Xie, Daniel Sullivan, Keith Usiskin, William Canovatchel,[...]. Diabetologia 2015
20
Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease.
Dick de Zeeuw, Tadao Akizawa, Paul Audhya, George L Bakris, Melanie Chin, Heidi Christ-Schmidt, Angie Goldsberry, Mark Houser, Melissa Krauth, Hiddo J Lambers Heerspink,[...]. N Engl J Med 2013
Dick de Zeeuw, Tadao Akizawa, Paul Audhya, George L Bakris, Melanie Chin, Heidi Christ-Schmidt, Angie Goldsberry, Mark Houser, Melissa Krauth, Hiddo J Lambers Heerspink,[...]. N Engl J Med 2013
20
Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.